AI Article Synopsis

  • A study found that rare variants in the PLD3 gene are linked to an increased risk of late-onset Alzheimer disease (LOAD).
  • Researchers identified a specific missense mutation in a patient with Alzheimer who started showing symptoms at age 50 and then expanded their analysis to other European cohorts.
  • Despite identifying 22 rare variants in PLD3, the research did not show significant evidence linking these variants to early-onset Alzheimer disease (EOAD), suggesting that PLD3 may not play a genetic role in the condition.

Article Abstract

Rare variants in the phospholipase D3 gene (PLD3) were associated with increased risk for late-onset Alzheimer disease (LOAD). We identified a missense mutation in PLD3 in whole-genome sequence data of a patient with autopsy confirmed Alzheimer disease (AD) and onset age of 50 years. Subsequently, we sequenced PLD3 in a Belgian early-onset Alzheimer disease (EOAD) patient (N = 261) and control (N = 319) cohort, as well as in European EOAD patients (N = 946) and control individuals (N = 1,209) ascertained in different European countries. Overall, we identified 22 rare variants with a minor allele frequency <1%, 20 missense and two splicing mutations. Burden analysis did not provide significant evidence for an enrichment of rare PLD3 variants in EOAD patients in any of the patient/control cohorts. Also, meta-analysis of the PLD3 data, including a published dataset of a German EOAD cohort, was not significant (P = 0.43; OR = 1.53, 95% CI 0.60-3.31). Consequently, our data do not support a role for PLD3 rare variants in the genetic etiology of EOAD in European EOAD patients. Our data corroborate the negative replication data obtained in LOAD studies and therefore a genetic role of PLD3 in AD remains to be demonstrated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5057316PMC
http://dx.doi.org/10.1002/humu.22908DOI Listing

Publication Analysis

Top Keywords

alzheimer disease
16
rare variants
12
early-onset alzheimer
8
pld3
4
variants pld3
4
pld3 affect
4
affect risk
4
risk early-onset
4
alzheimer
4
disease
4

Similar Publications

Background: Research has shown that engaging in a range of healthy lifestyles or behavioral factors can help reduce the risk of developing dementia. Improved knowledge of modifiable risk factors for dementia may help engage people to reduce their risk, with beneficial impacts on individual and public health. Moreover, many guidelines emphasize the importance of providing education and web-based resources for dementia prevention.

View Article and Find Full Text PDF

With the increasing number of patients with Alzheimer's Disease (AD), the demand for early diagnosis and intervention is becoming increasingly urgent. The traditional detection methods for Alzheimer's disease mainly rely on clinical symptoms, biomarkers, and imaging examinations. However, these methods have limitations in the early detection of Alzheimer's disease, such as strong subjectivity in diagnostic criteria, high detection costs, and high misdiagnosis rates.

View Article and Find Full Text PDF

Influence of lung function on macro- and micro-structural brain changes in mid- and late-life.

Int J Surg

January 2025

Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Introduction: Lung function has been associated with cognitive decline and dementia, but the extent to which lung function impacts brain structural changes remains unclear. We aimed to investigate the association of lung function with structural macro- and micro-brain changes across mid- and late-life.

Methods: The study included a total of 37 164 neurologic disorder-free participants aged 40-70 years from the UK Biobank, who underwent brain MRI scans 9 years after baseline.

View Article and Find Full Text PDF

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by cognitive decline. Despite extensive research, therapeutic options remain limited. Varenicline, an αβ nicotinic acetylcholine receptor agonist, shows promise in enhancing cognitive function.

View Article and Find Full Text PDF

Neurodegeneration is presumed to be the pathological process measure most proximal to clinical symptom onset in Alzheimer Disease (AD). Structural MRI is routinely collected in research and clinical trial settings. Several quantitative MRI-based measures of atrophy have been proposed, but their low correspondence with each other has been previously documented.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!